Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 170Neoplasms 66Carcinoma, Non-Small-Cell Lung 49Neoplasm Metastasis 37Unspecified Adult Solid Tumor, Protocol Specific 25Ovarian Neoplasms 21Breast Neoplasms 21Urinary Bladder Neoplasms 20Cholangiocarcinoma 20Lymphoma 19Colorectal Neoplasms 18Lymphoma, Non-Hodgkin 17Lung Neoplasms 17Sarcoma 16Hodgkin Disease 14Fallopian Tube Neoplasms 14Biliary Tract Neoplasms 13Lymphoma, Large B-Cell, Diffuse 12Gallbladder Neoplasms 11Colonic Neoplasms 11Carcinoma, Ovarian Epithelial 11Stomach Neoplasms 10Recurrence 10Solid Tumors 9Bile Duct Neoplasms 8Adenocarcinoma 8Triple Negative Breast Neoplasms 7Small Cell Lung Carcinoma 7Rectal Neoplasms 7Melanoma 7

Interventions

Cisplatin 2vactosertib 1fludarabine 1enzalutamide 1bintrafusp alfa protein, human 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Paclitaxel 1LY3300054 1Gemcitabine 1Fenretinide 1Cyclophosphamide 1Carboplatin 1Bevacizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Camurati-Engelmann Syndrome × Gemcitabine × Clear all
NCT02937272 2026-04-03

A Study of LY3200882 in Participants With Solid Tumors

Eli Lilly and Company

Phase 1 Active not recruiting
223 enrolled

Camurati-Engelmann Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡